Press Releases April 15, 2026 08:00 PM

BOSS Zhipin's Sustained Share Repurchases Achieved Nearly RMB880 Million in 2026

KANZHUN LIMITED continues aggressive share buyback program in 2026, deploying nearly RMB880 million to enhance shareholder value.

By Nina Shah BZ
BOSS Zhipin's Sustained Share Repurchases Achieved Nearly RMB880 Million in 2026
BZ

KANZHUN LIMITED, operating as BOSS Zhipin and listed on Nasdaq (BZ), announced ongoing share repurchases in 2026, having bought back shares worth nearly RMB880 million so far this year. The recent repurchase of over RMB17.0 million for 349,516 shares on April 15 emphasizes the company's strong commitment to returning value to shareholders.

Key Points

  • KANZHUN LIMITED has repurchased nearly RMB880 million worth of shares in 2026 year-to-date.
  • The company executed a recent buyback on April 15, purchasing 349,516 shares at RMB17.0 million.
  • The share repurchase program signals commitment to shareholder returns and confidence in the company's prospects.

BEIJING, April 16, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB17.0 million to repurchase 349,516 ordinary shares on April 15. Year-to-date in 2026, the Company has deployed nearly RMB880 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued allocation of capital to buybacks may limit funds available for operational growth or other investments.
  • Share repurchase effectiveness depends on market conditions and stock price, which can fluctuate.
  • There could be regulatory risks or market perception risks if buybacks are seen as masking underlying business challenges.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026